Circulating and Extracellular Vesicles Levels of N-(1-Carboxymethyl)-L-Lysine (CML) Differentiate Early to Moderate Alzheimer’s Disease

Mohamed Haddad (1, 2) , Morgane Perrotte (1, 2) , Sarra Landri (1, 2) , Aurelie Lepage (3) , Tamas Fulöp (3) , Charles Ramassamy (2, 1)

1 INRS-IAF - Institut Armand Frappier
2 INAF - Institut sur la Nutrition et les Aliments Fonctionnels [université Laval, Québec]
3 CSSS-IUGS - Centre de Recherche sur le Vieillissement

Both advanced glycation end products (AGEs) N-(1-carboxymethyl)-L-lysine (CML) and pentosidine were found in the brain from Alzheimer's disease (AD) patients and were associated with the neuropathological hallmarks of AD. In AD patients, the circulating level of both AGEs remains unknown. Moreover, their levels in peripheral extracellular vesicles (EVs) and their association with AD remain to be determined. Finally, it is not known if neuronal cells can release AGEs via EVs and propagate AGEs.

Keywords: Alzheimer’s disease; Mini-Mental State Examination (MMSE); Montreal Cognitive Assessment (MoCA); carboxymethyl lysine (CML); extracellular vesicles; pentosidine

Domains: Life Sciences [q-bio]; Life Sciences [q-bio]; Neurons and Cognition [q-bio.NC]; Life Sciences [q-bio]; Human health and pathology; Geriatry and gerontology

Mohamed Haddad, Morgane Perrotte, Sarra Landri, Aurelie Lepage, Tamas Fulöp, et al.. Circulating and Extracellular Vesicles Levels of N-(1-Carboxymethyl)-L-Lysine (CML) Differentiate Early to Moderate Alzheimer’s Disease. Journal of Alzheimer's Disease, 2019, 69 (3), pp.751-762. ⟨10.3233/JAD-181272⟩. ⟨pasteur-02275370⟩